Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

Clinical Microbiology and Infection

Volumn 21, Issue 2, 2015, Pages 205.e1-205.e3

  Boglione, L ^a   De Nicolo A ^a   Cardellino, C S ^a   Ruggiero, T ^a   Ghisetti, V ^a   Cariti, G ^a   Di Perri, G ^a   D'Avolio, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Boceprevir; Breakthrough; HCV; Resistance; Triple therapy

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOMER; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CHEMISTRY; CLASSIFICATION; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MISSENSE MUTATION; PLASMA; PROCEDURES; TREATMENT FAILURE;

HEPATITIS C VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG MONITORING; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMA; PROLINE; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT FAILURE;

EID: 84922981045     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.07.009     Document Type: Article

References (16)

1. Mohd Hanafiah K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEngl J Med 2002, 347:975-982.
3. Hezode C., Dorival C., Zoulim F., Poynard T., Mathurin P., Pol S., et al. Safety of telaprevir or boceprevir in combination with peginterferonalfa/ribavirin in cirrhotic non responders: first results of the French early access program (ANRS CO20-CUPIC). JHepatol 2012, 56:S4.
4. Vermehren J., Susser S., Lange C.M., Forestier N., Karey U., Hughes E., et al. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. JViral Hepat 2012, 19:120-127.
5. Susser S., Welsch C., Wang Y., Zettler M., Domingues F.S., Karey U., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
6. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006, 70:28-38.
7. Wyles D.L. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012, 20:139-145.
8. Barnard R.J., Howe J.A., Ogert R.A., et al. Analysis of boceprevir resistance associated amino acid variants (RAVS) in two phase 3 boceprevir clinical studies. Virology 2013, 444:329-336.
9. D'Avolio A., De Nicolo A., Agnesod D., Simiele M., Mohamed Abdi A., Dilly Penchala S., et al. AUPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. JPharm Biomed Anal 2013, 78-79:217-223.
10. D'Avolio A., Ibanez A., Sciandra M., de Requena D.G., Bonora S., Di Perri G. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. JChromatogr B Analyt Technol Biomed Life Sci 2006, 835:127-130.
11. Kieffer T.L., De Meyer S., Bartels D.J., Sullivan J.C., Zhang E.Z., Tigges A., et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012, 7:e34372.
12. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
13. Nelson D.R. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 2011, 31(suppl. 1):53-57.
14. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Joung S.K., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769-1778.
15. Pawlotsky J.M. The results of phase iii clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011, 140:746-754.
16. Chen K.X., Njoroge F.G. The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. Prog Med Chem 2010, 49:1-36.